Julie Lamb

About the Author Julie Lamb

Julie graduated with a Bachelor of Arts in English with a focus on creative writing from the University of Louisville.

Friday’s Market Insights: Interpace Diagnostics Group Inc (IDXG), Skyworks Solutions Inc (SWKS), and Bellerophon Therapeutics Inc (BLPH)


The following three stocks are climbing today: Interpace Diagnostics Group Inc (NASDAQ:IDXG), Skyworks Solutions Inc (NASDAQ:SWKS), and Bellerophon Therapeutics Inc (NASDAQ:BLPH). What factors have led to these upswings?

We explore as Interpace shares are accelerating in wake of a pivotal deal struck with Israeli company Best Med Opinion Ltd., SWKS levels are taking wing after a strong earnings performance in its first fiscal quarter for 2017, and Bellerophon investors are listening to H.C. Wainwright’s first call backing the stock with full confidence.

Let’s dive in:

Interpace Strikes Deal with Best Med to Open International Doors

Interpace shares are rising almost 62% on the heels of the biotech firm entering a strategic pact with Tel Aviv, Israel company Best Med Opinion Ltd. The terms of the collaboration will enable the Israeli company to inform physicians and patients alike as to IDXG’s tests for its oncology pipeline: ThyGenX, ThyraMir, and PancraGen.

Additionally, BestMed will know when IDXG’s tests are chosen to reinforce and shape treatment plans, guide the overall collecting and shipping strategy of samples to IDXG’s CLIA laboratories, and inform the ordering physician of the final results. Essentially, the agreement renders the Israeli company as IDXG’s exclusive provider of products for Israel.

Why is this such a significant step forward for Interpace? The firm has its eyes set on traversing beyond the U.S. market, and this deal enables IDXG’s products to steamroll towards the objective of developing international prospects. The Interpace team sees a heightened push for a public that seeks its molecular diagnostic innovations, likely a reason motivating the deal with BestMed. In light of the collaboration, Israeli providers will have access to all of IDXG’s available line of molecular diagnostic products.

Best Med CEO Eran Lazar notes excitement for this advantageous alliance, opining, “We are very enthusiastic about our partnership with Interpace. Their products fill an important role in our efforts to provide physicians and patients with access to the best diagnostic tools available to help inform treatment decisions.”

Overall, Interpace President and CEO Jack Stover believes this deal will be the key to developing global prospects, concluding, “We are excited about our relationship with Best Med. Their selection of our products and services is an important validation of our potential to expand internationally.”

Skyworks Delivers Robust Q1:17 Print and Drexel Hamilton Cheers

SWKS investors sent shares soaring 8% after releasing first fiscal quarter results for 2017 that outperformed expectations.

In reaction, top analyst Cody Acree at Drexel Hamilton reiterates a Buy rating on SWKS while boosting the price target from $90 to $105, which implies a just under 24% upside from where the stock is currently trading.

For the first fiscal quarter of 2017, the chip giant posted $1.61 in EPS, just ahead of this time last year’s EPS of $1.60, and a welcome outclass for investors when considering the Street called for $1.58.

Acree asserts, “With a healthy global end-of-year smartphone demand, stable-to-growing market share, and diversity from its Broad Markets business, SWKS turned in a solid Q1, beating both sales and EPS projections, and gave better than expected guidance.”

Moreover, the analyst draws special attention to the giant’s promising guidance, noting, “We are particularly encouraged that 2Q guidance is for Skyworks’ first return to annual growth since this time last year, with March backlog fully covered and Broad Markets helping to offset normal smartphone seasonality.”

Ultimately, the sky is the limit for Skyworks from this top analyst’s eyes. “We believe SWKS is well positioned to capitalize on the industry’s migration to high-performance system-level solutions, as evidenced by its stable to growing market share at Apple, Samsung, Huawei, and the leading Tier-1 Chinese OEMs,” Acree surmises.

Cody Acree has a very good TipRanks score with a 71% success rate and a high standing of #89 out of 4,365 analysts. Acree realizes 18.9% in his annual returns. When recommending SWKS, Acree yields 48.6% in average profits on the stock.

TipRanks analytics show SWKS as a Buy. Based on 16 analysts polled by TipRanks in the last 3 months, 10 rate a Buy on SWKS while 6 maintain a Hold. The 12-month average price target stands at $91.60, marking a 4% upside from where the shares last closed.

H.C. Wainwright Initiates a Bullish Call on Bellerophon; Sees 59% Upside for the Stock

BLPH shares are soaring a solid 22% today, incited by H.C. Wainwright analyst Andrew Fein‘s initiation of coverage on Bellerophon’s prospects from a bullish perspective. In the analyst’s research report, he commends the biotech firm’s upside potential, initiating a Buy rating on BLPH shares with a price target of $5.00, which represents a 59% increase from current levels.

Fein sees rival advantage for the firm, explaining, “We believe Bellerophon’s portable, user-friendly device, INOpulse, offers a competitive value proposition as adjuvant therapy for PAH patients already on long-term oxygen support. We take a reductionist approach here and argue that despite the business development potential of INOpulse in the larger indications (i.e., PH-COPD and PH-IPF), a price target of $5/share can be fully supported by INOpulse in PAH alone.”

Looking ahead, “We conservatively model for a worldwide peak revenue of $238M (we discount this by 66% to get $157M for our valuation) for INOpulse in PAH by the year 2023. Ahead of the readouts from the two Phase 2 studies of INOpulse in PH-COPD and PH-IPF on tap for 1H17 that may offer additional upside, as well as the interim readout from the Phase 3 INO-1 of INOpulse in PAH on tap for YE17, we are initiating coverage with a Buy rating,” Fein contends.

According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, one-star analyst Andrew Fein is ranked #3,422 out of 4,365 analysts. Fein has a 38% success rate and loses 0.9% in his yearly returns. When recommending BLPH, Fein earns 0.0% in average profits on the stock.

TipRanks analytics indicate BLPH as a Strong Buy. Out of 3 analysts polled by TipRanks in the last 3 months, all 3 are bullish on Bellerophon stock. With a return potential of 914%, the stock’s consensus target price stands at $7.00.

You can learn how to set up your own top-notch biotech portfolio here.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts